Company intelligence / Profile preview

CZ BioMed Corp

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

Developing RVLYSIS, a genetically engineered oncolytic RSV that selectively kills tumor cells; one reported case of a stage 4 colon cancer patient receiving 48 doses and becoming cancer-free, but lacks formal clinical data

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapy
Industry: Biotech

Drug pipeline

7 assets

LURVLYSIS

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Asan Medical Center (via Well Marker Bio Co. Ltd.)Kocal Consulting CorporationUniversity of Texas Health Science Center at San Antonio (patent license)

Beyond the preview

Go deeper on CZ BioMed Corp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CZ BioMed Corp.

Explore the full profile